Drug Trial Radar · NCT05252754
Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis
Last checked: Nov 19, 2026Latest source record: Dec 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
4,874
Planned (sponsor's estimate)
Start
Jan 18, 2023
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Johns Hopkins UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research is being done to see if using oral tacrolimus before endoscopy, can prevent pancreatitis that may occur after ERCP (a type of gastrointestinal endoscopy).
Conditions
- Post-ERCP Acute Pancreatitis
Interventions
Tacrolimus capsuleDrug
Tacrolimus 5 mg PO, 1-2 hours prior to endoscopy
PlaceboDrug
Placebo PO, 1-2 hours prior to endoscopy.
Rectal IndomethacinDrug
100 mg Rectal Indomethacin immediately after ERCP, in high-risk patients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of subjects in each study group with Post ERCP Acute Pancreatitis (PEP)Time frame: Within 30 days of ERCP
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
Johns Hopkins Hospital
Baltimore, Maryland · Recruiting
Post Graduate Institute of Medical Education and Research
Chandigarh, India · Not yet recruiting
Asian Institute of Gastroenterology
Hyderabad, Andhra Pradesh, India · Recruiting
Apollo Multispecialty Hospitals,
Kolkata, West Bengal, India · Not yet recruiting
Singapore General Hospital
Singapore, Singapore · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.